N. Silvestre

发表

TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice

J. Marchand, A. van Dorsselaer, J. Strub, 2014, Gut.

Evaluation of heterologous prime-boost vaccination strategies using chimpanzee adenovirus and modified vaccinia virus for TB subunit vaccination in rhesus macaques

H. J. Borish, F. Verreck, Dominick J. Laddy, 2020, npj Vaccines.

Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators

J. Lagarde, K. Bystricky, J. Foloppe, 2020, Biomedicines.

Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition

L. Zitvogel, J. Marchand, P. Erbs, 2016, Oncoimmunology.

The sero-prevalence of anti-adenovirus 5 neutralizing antibodies is independent of a chronic hepatitis B carrier state in China

De-min Yu, Yue Han, Xinxin Zhang, 2015, Archives of Virology.

Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination

P. Erbs, K. Rittner, Fiorella Kotsias, 2022, Clinical & translational immunology.

Identical cis-acting elements and related trans-acting factors control activity of nonviral promoter in Schizosaccharomyces pombe and mammalian cells.

L. Nelles, D. Huylebroeck, J. Remacle, 1998, DNA and cell biology.

Solvoplex: a new type of synthetic vector for intrapulmonary gene delivery.

K. Schughart, R. Bischoff, O. Boussif, 1999, Human gene therapy.

Comparative analysis of immunization schedules using a novel adenovirus-based immunotherapeutic targeting hepatitis B in naïve and tolerant mouse models.

G. Inchauspé, P. Riedl, T. Menguy, 2014, Vaccine.

A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis

J. Marchand, P. Cardona, P. Converse, 2018, PloS one.

Up to 100-Fold Increase of Apparent Gene Expression in the Presence of Epstein-Barr Virus oriP Sequences and EBNA1: Implications of the Nuclear Import of Plasmids

V. Patzel, G. Sczakiel, K. Rittner, 1998, Journal of Virology.

Specific tumor cell targeting by a recombinant MVA expressing a functional single chain antibody on the surface of intracellular mature virus (IMV) particles.

M. Kieny, J. Taylor‐Papadimitriou, D. Snary, 2007, Viral immunology.

Characterization of upstream activating sequences involved in activation and regulation of pho4 expression in Schizosaccharomyces pombe

E. Jacobs, N. Silvestre, 1997, Molecular and General Genetics MGG.

Viral Delivery of IL-7 Is a Potent Immunotherapy Stimulating Innate and Adaptive Immunity and Confers Survival in Sepsis Models

J. Marchand, K. Lélu, Perrine J Martin, 2022, The Journal of Immunology.

Adaptive Immunity and Confers Survival in Immunotherapy Stimulating Innate and Viral Delivery of IL-7 Is a Potent

Marchand, K. Lélu, Perrine J Martin, 2022 .

By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1

J. Marchand, J. Foloppe, P. Erbs, 2019, Journal of Virology.

A meta-analysis of the antiviral activity of the HBV-specific immunotherapeutic TG1050 confirms its value over a wide range of HBsAg levels in a persistent HBV pre-clinical model

K. Lélu, Perrine J Martin, D. Schmitt, 2018, Human vaccines & immunotherapeutics.

An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses.

L. Chatel, A. Fournillier, E. Gerossier, 2007, Vaccine.

Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer

J. Greenbaum, Bjoern Peters, K. Boukas, 2022, Journal for ImmunoTherapy of Cancer.

A Novel MVA-Based Multiphasic Vaccine for Prevention or Treatment of Tuberculosis Induces Broad and Multifunctional Cell-Mediated Immunity in Mice and Primates

J. Marchand, A. Cristillo, E. Tupin, 2015, PloS one.

Immunological Characterization of a Modified Vaccinia Virus Ankara Vector Expressing the Human Papillomavirus 16 E1 Protein

J. Bonnefoy, C. Germain, X. Préville, 2013, Clinical and Vaccine Immunology.

Evaluation of heterologous prime-boost vaccination strategies using chimpanzee adenovirus and modified vaccinia virus for TB subunit vaccination in rhesus macaques

H. J. Borish, F. Verreck, Dominick J. Laddy, 2020, npj Vaccines.

Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject ‘cold’ tumors

J. Marchand, J. Foloppe, Jules Deforges, 2022, Journal for ImmunoTherapy of Cancer.

Abstract 5602: BT-001, an oncolytic vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment

J. Marchand, J. Foloppe, B. Frendéus, 2020 .

BT-001, AN ONCOLYTIC VACCINIA VIRUS ARMED WITH A TREG-DEPLETING HUMAN RECOMBINANT ANTI-CTLA4 ANTIBODY AND GM-CSF TO TARGET THE TUMOR MICROENVIRONMENT

B. Frendéus, I. Teige, Laetitia Fend, 2020 .

The sero-prevalence of anti-adenovirus 5 neutralizing antibodies is independent of a chronic hepatitis B carrier state in China

De-min Yu, Yue Han, Xinxin Zhang, 2015, Archives of Virology.